References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
- Cao M, Chen W. Epidemiology of lung cancer in China. Thoracic Cancer. 2019;10(1):3–7. doi:10.1111/1759-7714.12916
- Low M, Ben-Or S. Thoracic surgery in early-stage small cell lung cancer. Thorac Surg Clin. 2018;28(1):9–14. doi:10.1016/j.thorsurg.2017.08.003
- Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. doi:10.1016/j.ccm.2019.10.001
- O’Dowd EL, Baldwin DR. Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps. Br J Radiol. 2018;91(1090):20170460. doi:10.1259/bjr.20170460
- Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
- Ruytinx P, Proost P, Struyf S. CXCL4 and CXCL4L1 in cancer. Cytokine. 2018;109:65–71. doi:10.1016/j.cyto.2018.02.022
- Green CJ, Charles RS, Edwards BF, Johnson PH. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol Cell Biol. 1989;9(4):1445–1451. doi:10.1128/mcb.9.4.1445-1451.1989
- Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247(4938):77–79. doi:10.1126/science.1688470
- Zhang M, Guan J, Huo YL, Song YS, Chen LZ. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy. Asian J Androl. 2019;21(4):387–392. doi:10.4103/aja.aja_117_18
- Struyf S, Burdick MD, Peeters E, et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007;67(12):5940–5948. doi:10.1158/0008-5472.CAN-06-4682
- Eggert JA, Palavanzadeh M, Blanton A. Screening and early detection of lung cancer. Semin Oncol Nurs. 2017;33(2):129–140. doi:10.1016/j.soncn.2017.03.001
- Nanavaty P, Alvarez MS, Alberts WM. Lung cancer screening: advantages, controversies, and applications. Cancer Control. 2014;21(1):9–14. doi:10.1177/107327481402100102
- Snowsill T, Yang H, Griffin E, et al. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Health Technol Assess. 2018;22(69):1–276. doi:10.3310/hta22690
- Verbeke H, De Hertogh G, Li S, et al. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer. Hum Pathol. 2010;41(7):990–1001. doi:10.1016/j.humpath.2009.09.021
- Furuya M, Tanaka R, Miyagi E, et al. Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis. Cancer Biol Ther. 2012;13(8):671–680. doi:10.4161/cbt.20084
- Quemener C, Baud J, Boyé K, et al. Dual roles for CXCL4 chemokines and CXCR3 in angiogenesis and invasion of pancreatic cancer. Cancer Res. 2016;76(22):6507–6519. doi:10.1158/0008-5472.CAN-15-2864